Our results further indicate that activation of PTPN2 might be a very promising therapeutic approach for a broad range of chronic inflammatory and autoimmune disorders, including systemic lupus erythematosus, type-1-diabetes, rheumatoid arthritis, and psoriasis. The gene discussed is PTPN2; the disease is systemic lupus erythematosus.